CTOs on the Move


 
Earli has been funded by Andreessen Horowitz`s Bio Fund, Khosla, Perceptive Advisors, Casdin Capital, Sands Capital, Marc Benioff, Menlo Ventures, ZhenFund. Earli is based in the West Coast`s prime biotech hub in South San Francisco.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.earli.com
  • 161 Oyster Point Blvd Suite 201
    South San Francisco, CA USA 94080
  • Phone: N/A

Executives

Name Title Contact Details

Funding

Earli raised $40M on 01/12/2021

Similar Companies

Center For Innovation Inc

Center For Innovation Inc is a Butte, MT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Calyxt

Calyxt, Inc. is a consumer-centric, food- and agriculture-focused company based in Roseville, Minnesota. Our mission is to address health challenges such as obesity, diabetes, high cholesterol and food allergies by developing healthier food ingredients that produce high-quality, convenient and delicious food, while also providing agriculturally advantageous crop traits to farmers. As a leader in our field, our team is positively changing the way Americans eat by pioneering a paradigm shift to help make the food you love a healthier choice™.

Vor Biopharma

Vor Biopharma is pioneering engineered hematopoietic stem cells (eHSCs) to dramatically change the treatment paradigm for hematological cancers. Vor`s eHSCs are designed to generate healthy, fully functional cells with specific advantageous modifications, for example to protect the blood and bone marrow from the toxic effects of antigen-targeted therapies, protecting healthy cells from depletion but leaving tumor cells vulnerable. Vor`s platform could potentially be used to change the treatment paradigm of both hematopoietic stem cell transplants and antigen-targeted therapies such as antibody drug conjugates, bispecific antibodies and CAR-T cell treatments. A proof-of-concept study for Vor`s lead program has been published in Proceedings of the National Academy of Sciences. Vor is based in Cambridge, Mass. and has a broad intellectual property base including in-licenses from Columbia University, where foundational work was conducted by inventor and Vor Scientific Board Chair Siddhartha Mukherjee, MD, DPhil. Vor was founded by Dr. Mukherjee and PureTech Health and is supported by leading investors including 5AM Ventures and RA Capital Management, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Novartis Institutes for BioMedical Research and Osage University Partners.

Axcella Health

Axcella is designing and developing AXA Candidates, compositions of endogenous metabolic modulators, or EMMs, engineered in distinct ratios, designed to target and maximize the fundamental role that EMMs play in regulating multiple metabolic functions. Axcella`s AXA Candidates are generated from its proprietary, human-focused AXA Development Platform. Axcella believes its expertise and capabilities in EMMs position it to become a preeminent biotechnology company reprogramming metabolism to address a diverse set of complex diseases and support health. Axcella`s AXA Development Platform has already produced a pipeline of product candidates in programs targeting liver, muscle and blood. Axcella was founded by Flagship Pioneering.